Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1416 in Moderate to Severe Asthma
NCT07403487Phase 2Recruiting
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of RC1416 in asthma, sponsored by Nanjing RegeneCore Biotech Co., Ltd.. Started Mar 2026; status: recruiting.
02
Drugs
RC1416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07403487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403487.